Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 2/2017

01-06-2017

Platelet “first responders” in wound response, cancer, and metastasis

Authors: David G. Menter, Scott Kopetz, Ernest Hawk, Anil K. Sood, Jonathan M. Loree, Paolo Gresele, Kenneth V. Honn

Published in: Cancer and Metastasis Reviews | Issue 2/2017

Login to get access

Abstract

Platelets serve as “first responders” during normal wounding and homeostasis. Arising from bone marrow stem cell lineage megakaryocytes, anucleate platelets can influence inflammation and immune regulation. Biophysically, platelets are optimized due to size and discoid morphology to distribute near vessel walls, monitor vascular integrity, and initiate quick responses to vascular lesions. Adhesion receptors linked to a highly reactive filopodia-generating cytoskeleton maximizes their vascular surface contact allowing rapid response capabilities. Functionally, platelets normally initiate rapid clotting, vasoconstriction, inflammation, and wound biology that leads to sterilization, tissue repair, and resolution. Platelets also are among the first to sense, phagocytize, decorate, or react to pathogens in the circulation. These platelet first responder properties are commandeered during chronic inflammation, cancer progression, and metastasis. Leaky or inflammatory reaction blood vessel genesis during carcinogenesis provides opportunities for platelet invasion into tumors. Cancer is thought of as a non-healing or chronic wound that can be actively aided by platelet mitogenic properties to stimulate tumor growth. This growth ultimately outstrips circulatory support leads to angiogenesis and intravasation of tumor cells into the blood stream. Circulating tumor cells reengage additional platelets, which facilitates tumor cell adhesion, arrest and extravasation, and metastasis. This process, along with the hypercoagulable states associated with malignancy, is amplified by IL6 production in tumors that stimulate liver thrombopoietin production and elevates circulating platelet numbers by thrombopoiesis in the bone marrow. These complex interactions and the “first responder” role of platelets during diverse physiologic stresses provide a useful therapeutic target that deserves further exploration.
Literature
1.
Menter, D. G., Tucker, S. C., Kopetz, S., Sood, A. K., Crissman, J. D., & Honn, K. V. (2014). Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Reviews, 33(1), 231–269.PubMedPubMedCentralCrossRef
2.
Menter, D., Davis, J., Tucker, S., Hawk, E., Crissman, J., Sood, A., et al. (2017). Platelets “First Responders” in cancer progression and metastasis. In P. Gresele, N. Kleiman, J. Lopez, & C. Page (Eds.), Platelets in thrombotic and non-thrombotic disorders (Vol. 2, pp. 1111–1132). Switzerland: Springer International Publishing.CrossRef
3.
Leunissen, T. C., Wisman, P. P., van Holten, T. C., de Groot, P. G., Korporaal, S. J., Koekman, A. C., et al. (2016). The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays. Platelets, 1–9.
4.
Liu, X., Li, Y., Zhu, H., Zhao, Z., Zhou, Y., Zaske, A. M., et al. (2015). Use of non-contact hopping probe ion conductance microscopy to investigate dynamic morphology of live platelets. Platelets, 26(5), 480–485.PubMedCrossRef
5.
Lof, A., Muller, J. P., Benoit, M., & Brehm, M. A. (2017). Biophysical approaches promote advances in the understanding of von Willebrand factor processing and function. Advances in Biological Regulation, 63, 81–91.PubMedCrossRef
6.
Heijnen, H., & Korporaal, S. (2017). Platelet morphology and ultrastructure. In P. Gresele, N. Kleiman, J. Lopez, & C. Page (Eds.), Platelets in thrombotic and non-thrombotic disorders (Vol. 2, pp. 21–37). Switzerland: Springer International Publishing.CrossRef
7.
O'Brien, S., Kent, N. J., Lucitt, M., Ricco, A. J., McAtamney, C., Kenny, D., et al. (2012). Effective hydrodynamic shaping of sample streams in a microfluidic parallel-plate flow-assay device: matching whole blood dynamic viscosity. IEEE Transactions on Biomedical Engineering, 59(2), 374–382.PubMedCrossRef
8.
Jen, C. J., & Tai, Y. W. (1992). Morphological study of platelet adhesion dynamics under whole blood flow conditions. Platelets, 3(3), 145–153.PubMedCrossRef
9.
Folie, B. J., & McIntire, L. V. (1989). Mathematical analysis of mural thrombogenesis. Concentration profiles of platelet-activating agents and effects of viscous shear flow. Biophysical Journal, 56(6), 1121–1141.PubMedPubMedCentralCrossRef
10.
Fedosov, D. A., Noguchi, H., & Gompper, G. (2014). Multiscale modeling of blood flow: from single cells to blood rheology. Biomechanics and Modeling in Mechanobiology, 13(2), 239–258.PubMedCrossRef
11.
Kumar, A., & Graham, M. D. (2012). Mechanism of margination in confined flows of blood and other multicomponent suspensions. Physical Review Letters, 109(10), 108102.PubMedCrossRef
12.
Tokarev, A. A., Butylin, A. A., & Ataullakhanov, F. I. (2011). Platelet adhesion from shear blood flow is controlled by near-wall rebounding collisions with erythrocytes. Biophysical Journal, 100(4), 799–808.PubMedPubMedCentralCrossRef
13.
Tokarev, A. A., Butylin, A. A., Ermakova, E. A., Shnol, E. E., Panasenko, G. P., & Ataullakhanov, F. I. (2011). Finite platelet size could be responsible for platelet margination effect. Biophysical Journal, 101(8), 1835–1843.PubMedPubMedCentralCrossRef
14.
Lee, S. Y., Ferrari, M., & Decuzzi, P. (2009). Design of bio-mimetic particles with enhanced vascular interaction. Journal of Biomechanics, 42(12), 1885–1890.PubMedCrossRef
15.
Stukelj, R., Schara, K., Bedina-Zavec, A., Sustar, V., Pajnic, M., Paden, L., et al. (2017). Effect of shear stress in the flow through the sampling needle on concentration of nanovesicles isolated from blood. European Journal of Pharmaceutical Sciences, 98, 17–29.PubMedCrossRef
16.
De Gruttola, S., Boomsma, K., & Poulikakos, D. (2005). Computational simulation of a non-newtonian model of the blood separation process. Artificial Organs, 29(12), 949–959.PubMedCrossRef
17.
Nesbitt, W. S., Westein, E., Tovar-Lopez, F. J., Tolouei, E., Mitchell, A., Fu, J., et al. (2009). A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nature Medicine, 15(6), 665–673.PubMedCrossRef
18.
Menter, D. G., Steinert, B. W., Sloane, B. F., Gundlach, N., O'Gara, C. Y., Marnett, L. J., et al. (1987). Role of platelet membrane in enhancement of tumor cell adhesion to endothelial cell extracellular matrix. Cancer Research, 47(24 Pt 1), 6751–6762.PubMed
19.
Crissman, J. D., Hatfield, J. S., Menter, D. G., Sloane, B., & Honn, K. V. (1988). Morphological study of the interaction of intravascular tumor cells with endothelial cells and subendothelial matrix. Cancer Research, 48(14), 4065–4072.PubMed
20.
Walsh, T. G., Metharom, P., & Berndt, M. C. (2015). The functional role of platelets in the regulation of angiogenesis. Platelets, 26(3), 199–211.PubMedCrossRef
21.
Kim, K. H., Barazia, A., & Cho, J. (2013). Real-time imaging of heterotypic platelet-neutrophil interactions on the activated endothelium during vascular inflammation and thrombus formation in live mice. Journal of Visualized Experiments, 74.
22.
Spectre, G., Zhu, L., Ersoy, M., Hjemdahl, P., Savion, N., Varon, D., et al. (2012). Platelets selectively enhance lymphocyte adhesion on subendothelial matrix under arterial flow conditions. Thrombosis and Haemostasis, 108(2), 328–337.PubMedCrossRef
23.
Gardiner, E., & Andrews, R. (2017). Platelet adhesion. In P. Gresele, N. Kleiman, J. Lopez, & C. Page (Eds.), Platelets in thrombotic and non-thrombotic disorders (Vol. 2, pp. 309–319). Switzerland: Springer International Publishing.CrossRef
24.
Pothapragada, S., Zhang, P., Sheriff, J., Livelli, M., Slepian, M. J., Deng, Y., et al. (2015). A phenomenological particle-based platelet model for simulating filopodia formation during early activation. International Journal of Numerical Methods in Biomedical Engineering, 31(3), e02702.CrossRef
25.
Kunert, S., Meyer, I., Fleischhauer, S., Wannack, M., Fiedler, J., Shivdasani, R. A., et al. (2009). The microtubule modulator RanBP10 plays a critical role in regulation of platelet discoid shape and degranulation. Blood, 114(27), 5532–5540.PubMedCrossRef
26.
Jackson, S. P., Nesbitt, W. S., & Westein, E. (2009). Dynamics of platelet thrombus formation. Journal of Thrombosis and Haemostasis, 7(Suppl 1), 17–20.PubMedCrossRef
27.
Italiano Jr., J. E., Bergmeier, W., Tiwari, S., Falet, H., Hartwig, J. H., Hoffmeister, K. M., et al. (2003). Mechanisms and implications of platelet discoid shape. Blood, 101(12), 4789–4796.PubMedCrossRef
28.
Hartwig, J. H., Barkalow, K., Azim, A., & Italiano, J. (1999). The elegant platelet: signals controlling actin assembly. Thrombosis and Haemostasis, 82(2), 392–398.PubMed
29.
White, J. G., & Rao, G. H. (1998). Microtubule coils versus the surface membrane cytoskeleton in maintenance and restoration of platelet discoid shape. The American Journal of Pathology, 152(2), 597–609.PubMedPubMedCentral
30.
Polanowska-Grabowska, R., Geanacopoulos, M., & Gear, A. R. (1993). Platelet adhesion to collagen via the alpha 2 beta 1 integrin under arterial flow conditions causes rapid tyrosine phosphorylation of pp125FAK. Biochemical Journal, 296(Pt 3), 543–547.PubMedPubMedCentralCrossRef
31.
Falet, H. (2017). Anatomy of the platelet cytoskeleton. In P. Gresele, N. Kleiman, J. Lopez, & C. Page (Eds.), Platelets in thrombotic and non-thrombotic disorders (Vol. 2, pp. 139–156). Switzerland: Springer International Publishing.CrossRef
32.
Nurden, A. T., & Nurden, P. (2014). Congenital platelet disorders and understanding of platelet function. British Journal of Haematology, 165(2), 165–178.PubMedCrossRef
33.
Coburn, L. A., Damaraju, V. S., Dozic, S., Eskin, S. G., Cruz, M. A., & McIntire, L. V. (2011). GPIbalpha-vWF rolling under shear stress shows differences between type 2B and 2M von Willebrand disease. Biophysical Journal, 100(2), 304–312.PubMedPubMedCentralCrossRef
34.
Colace, T. V., & Diamond, S. L. (2013). Direct observation of von Willebrand factor elongation and fiber formation on collagen during acute whole blood exposure to pathological flow. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(1), 105–113.PubMedCrossRef
35.
Fredrickson, B. J., Dong, J. F., McIntire, L. V., & Lopez, J. A. (1998). Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood, 92(10), 3684–3693.PubMed
36.
Jackson, S. P., Mistry, N., & Yuan, Y. (2000). Platelets and the injured vessel wall—“rolling into action”: focus on glycoprotein Ib/V/IX and the platelet cytoskeleton. Trends in Cardiovascular Medicine, 10(5), 192–197.PubMedCrossRef
37.
Yago, T., Lou, J., Wu, T., Yang, J., Miner, J. J., Coburn, L., et al. (2008). Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. The Journal of Clinical Investigation, 118(9), 3195–3207.PubMedPubMedCentral
38.
Clemetson, K. J. (2007). A short history of platelet glycoprotein Ib complex. Thrombosis and Haemostasis, 98(1), 63–68.PubMed
39.
Li, R., & Emsley, J. (2013). The organizing principle of the platelet glycoprotein Ib-IX-V complex. Journal of Thrombosis and Haemostasis, 11(4), 605–614.PubMedPubMedCentralCrossRef
40.
Bernard, J., & Soulier, J. (1948). Sur une nouvelle variété de dystrophie thrombocytaire-hémorragipare congénitale. Semin Hôp Paris, 24, 3217–3223.
41.
Ozaki, Y., Suzuki-Inoue, K., & Inoue, O. (2013). Platelet receptors activated via mulitmerization: glycoprotein VI, GPIb-IX-V, and CLEC-2. Journal of Thrombosis and Haemostasis, 11(Suppl 1), 330–339.PubMedCrossRef
42.
Bernardo, A., Ball, C., Nolasco, L., Choi, H., Moake, J. L., & Dong, J. F. (2005). Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. Journal of Thrombosis and Haemostasis, 3(3), 562–570.PubMedCrossRef
43.
De Ceunynck, K., De Meyer, S. F., & Vanhoorelbeke, K. (2013). Unwinding the von Willebrand factor strings puzzle. Blood, 121(2), 270–277.PubMedCrossRef
44.
Desch, A., Strozyk, E. A., Bauer, A. T., Huck, V., Niemeyer, V., Wieland, T., et al. (2012). Highly invasive melanoma cells activate the vascular endothelium via an MMP-2/integrin alphavbeta5-induced secretion of VEGF-A. The American Journal of Pathology, 181(2), 693–705.PubMedCrossRef
45.
Coller, B. S., & Shattil, S. J. (2008). The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood, 112(8), 3011–3025.PubMedPubMedCentralCrossRef
46.
Kim, C., & Kim, M. C. (2013). Differences in alpha-beta transmembrane domain interactions among integrins enable diverging integrin signaling. Biochemical and Biophysical Research Communications, 436(3), 406–412.PubMedCrossRef
47.
Kim, C., Lau, T. L., Ulmer, T. S., & Ginsberg, M. H. (2009). Interactions of platelet integrin alphaIIb and beta3 transmembrane domains in mammalian cell membranes and their role in integrin activation. Blood, 113(19), 4747–4753.PubMedPubMedCentralCrossRef
48.
Shattil, S. J. (2009). The beta3 integrin cytoplasmic tail: protein scaffold and control freak. Journal of Thrombosis and Haemostasis, 7(Suppl 1), 210–213.PubMedCrossRef
49.
Nurden, A. T., & Caen, J. P. (1974). An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia. British Journal of Haematology, 28(2), 253–260.PubMedCrossRef
50.
Phillips, D. R., Jenkins, C. S., Luscher, E. F., & Larrieu, M. (1975). Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes. Nature, 257(5527), 599–600.PubMedCrossRef
51.
Glanzmann, E. (1918). Hereditare hammorhagische thrombastehnie. Beitr Pathologie Bluplatchen J Kinderkt, 88, 113–141.
52.
Zhang, C., Zhang, L., Zhang, Y., Sun, N., Jiang, S., Fujihara, T. J., et al. (2016). Development of antithrombotic nanoconjugate blocking integrin alpha2beta1-collagen interactions. Scientific Reports, 6, 26292.PubMedPubMedCentralCrossRef
53.
Szanto, T., Joutsi-Korhonen, L., Deckmyn, H., & Lassila, R. (2012). New insights into von Willebrand disease and platelet function. Seminars in Thrombosis and Hemostasis, 38(1), 55–63.PubMedCrossRef
54.
Maurer, E., Schaff, M., Receveur, N., Bourdon, C., Mercier, L., Nieswandt, B., et al. (2015). Fibrillar cellular fibronectin supports efficient platelet aggregation and procoagulant activity. Thrombosis and Haemostasis, 114(6), 1175–1188.PubMedCrossRef
55.
McCarty, O. J., Zhao, Y., Andrew, N., Machesky, L. M., Staunton, D., Frampton, J., et al. (2004). Evaluation of the role of platelet integrins in fibronectin-dependent spreading and adhesion. Journal of Thrombosis and Haemostasis, 2(10), 1823–1833.PubMedCrossRef
56.
Schaff, M., Tang, C., Maurer, E., Bourdon, C., Receveur, N., Eckly, A., et al. (2013). Integrin alpha6beta1 is the main receptor for vascular laminins and plays a role in platelet adhesion, activation, and arterial thrombosis. Circulation, 128(5), 541–552.PubMedCrossRef
57.
Inoue, O., Suzuki-Inoue, K., McCarty, O. J., Moroi, M., Ruggeri, Z. M., Kunicki, T. J., et al. (2006). Laminin stimulates spreading of platelets through integrin alpha6beta1-dependent activation of GPVI. Blood, 107(4), 1405–1412.PubMedPubMedCentralCrossRef
58.
Clemetson, K. J. (1995). Platelet activation: signal transduction via membrane receptors. Thrombosis and Haemostasis, 74(1), 111–116.PubMed
59.
Moroi, M., Jung, S. M., Okuma, M., & Shinmyozu, K. (1989). A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. The Journal of Clinical Investigation, 84(5), 1440–1445.PubMedPubMedCentralCrossRef
60.
Asselin, J., Knight, C. G., Farndale, R. W., Barnes, M. J., & Watson, S. P. (1999). Monomeric (glycine-proline-hydroxyproline)10 repeat sequence is a partial agonist of the platelet collagen receptor glycoprotein VI. Biochemical Journal, 339(Pt 2), 413–418.PubMedPubMedCentralCrossRef
61.
Kehrel, B., Wierwille, S., Clemetson, K. J., Anders, O., Steiner, M., Knight, C. G., et al. (1998). Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not. Blood, 91(2), 491–499.PubMed
62.
Zahid, M., Mangin, P., Loyau, S., Hechler, B., Billiald, P., Gachet, C., et al. (2012). The future of glycoprotein VI as an antithrombotic target. Journal of Thrombosis and Haemostasis, 10(12), 2418–2427.PubMedCrossRef
63.
Li, P., Qiao, J. L., & Xu, K. L. (2017). Advances of studies on platelet GPVI as antithrombotic target—review. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 25(1), 264–269.PubMed
64.
Poulter, N. S., Pollitt, A. Y., Owen, D. M., Gardiner, E. E., Andrews, R. K., Shimizu, H., et al. (2017). Clustering of glycoprotein VI (GPVI) dimers upon adhesion to collagen as a mechanism to regulate GPVI signaling in platelets. Journal of Thrombosis and Haemostasis, 15(3), 549–564.PubMedPubMedCentralCrossRef
65.
Pierre, S., Linke, B., Suo, J., Tarighi, N., Del Turco, D., Thomas, D., et al. (2017). GPVI and thromboxane receptor on platelets promote proinflammatory macrophage phenotypes during cutaneous inflammation. The Journal of Investigative Dermatology, 137(3), 686–695.PubMedCrossRef
66.
Bergmeier, W., & Stefanini, L. (2013). Platelet ITAM signaling. Current Opinion in Hematology, 20(5), 445–450.PubMedCrossRef
67.
Takemoto, A., Okitaka, M., Takagi, S., Takami, M., Sato, S., Nishio, M., et al. (2017). A critical role of platelet TGF-beta release in podoplanin-mediated tumour invasion and metastasis. Scientific Reports, 7, 42186.PubMedPubMedCentralCrossRef
68.
Nakazawa, Y., Sato, S., Naito, M., Kato, Y., Mishima, K., Arai, H., et al. (2008). Tetraspanin family member CD9 inhibits aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis. Blood, 112(5), 1730–1739.PubMedCrossRef
69.
Navarro-Nunez, L., Langan, S. A., Nash, G. B., & Watson, S. P. (2013). The physiological and pathophysiological roles of platelet CLEC-2. Thrombosis and Haemostasis, 109(6), 991–998.PubMedPubMedCentralCrossRef
70.
Suzuki-Inoue, K., Fuller, G. L., Garcia, A., Eble, J. A., Pohlmann, S., Inoue, O., et al. (2006). A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood, 107(2), 542–549.PubMedCrossRef
71.
Suzuki-Inoue, K., Kato, Y., Inoue, O., Kaneko, M. K., Mishima, K., Yatomi, Y., et al. (2007). Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. The Journal of Biological Chemistry, 282(36), 25993–26001.PubMedCrossRef
72.
Pula, B., Witkiewicz, W., Dziegiel, P., & Podhorska-Okolow, M. (2013). Significance of podoplanin expression in cancer-associated fibroblasts: a comprehensive review. International Journal of Oncology, 42(6), 1849–1857.PubMed
73.
Watson, A. A., Brown, J., Harlos, K., Eble, J. A., Walter, T. S., & O'Callaghan, C. A. (2007). The crystal structure and mutational binding analysis of the extracellular domain of the platelet-activating receptor CLEC-2. The Journal of Biological Chemistry, 282(5), 3165–3172.PubMedCrossRef
74.
Watson, A. A., & O'Callaghan, C. A. (2005). Crystallization and X-ray diffraction analysis of human CLEC-2. Acta Crystallographica. Section F, Structural Biology and Crystallization Communications, 61(Pt 12), 1094–1096.PubMedPubMedCentralCrossRef
75.
Suzuki-Inoue, K., Inoue, O., & Ozaki, Y. (2011). Novel platelet activation receptor CLEC-2: from discovery to prospects. Journal of Thrombosis and Haemostasis, 9(Suppl 1), 44–55.PubMedCrossRef
76.
Johnston, G. I., Cook, R. G., & McEver, R. P. (1989). Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation. Cell, 56(6), 1033–1044.PubMedCrossRef
77.
Stenberg, P. E., McEver, R. P., Shuman, M. A., Jacques, Y. V., & Bainton, D. F. (1985). A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. The Journal of Cell Biology, 101(3), 880–886.PubMedCrossRef
78.
Zarbock, A., Muller, H., Kuwano, Y., & Ley, K. (2009). PSGL-1-dependent myeloid leukocyte activation. Journal of Leukocyte Biology, 86(5), 1119–1124.PubMedCrossRef
79.
Picker, L. J., Warnock, R. A., Burns, A. R., Doerschuk, C. M., Berg, E. L., & Butcher, E. C. (1991). The neutrophil selectin LECAM-1 presents carbohydrate ligands to the vascular selectins ELAM-1 and GMP-140. Cell, 66(5), 921–933.PubMedCrossRef
80.
Polley, M. J., Phillips, M. L., Wayner, E., Nudelman, E., Singhal, A. K., Hakomori, S., et al. (1991). CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize the same carbohydrate ligand, sialyl-Lewis x. Proceedings of the National Academy of Sciences of the United States of America, 88(14), 6224–6228.PubMedPubMedCentralCrossRef
81.
Foxall, C., Watson, S. R., Dowbenko, D., Fennie, C., Lasky, L. A., Kiso, M., et al. (1992). The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis(x) oligosaccharide. The Journal of Cell Biology, 117(4), 895–902.PubMedCrossRef
82.
Habets, K. L., Huizinga, T. W., & Toes, R. E. (2013). Platelets and autoimmunity. European Journal of Clinical Investigation, 43(7), 746–757.PubMedCrossRef
83.
Kazmi, R. S., Cooper, A. J., & Lwaleed, B. A. (2011). Platelet function in pre-eclampsia. Seminars in Thrombosis and Hemostasis, 37(2), 131–136.PubMedCrossRef
84.
Nurden, A. T. (2011). Platelets, inflammation and tissue regeneration. Thrombosis and Haemostasis, 105(Suppl 1), S13–S33.PubMedCrossRef
85.
Borsig, L. (2008). The role of platelet activation in tumor metastasis. Expert Review of Anticancer Therapy, 8(8), 1247–1255.PubMedCrossRef
86.
Dammacco, F., Vacca, A., Procaccio, P., Ria, R., Marech, I., & Racanelli, V. (2013). Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine. Clinical and Experimental Medicine, 13(2), 85–97.PubMedCrossRef
87.
Erpenbeck, L., & Schon, M. P. (2010). Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood, 115(17), 3427–3436.PubMedPubMedCentralCrossRef
88.
Gay, L. J., & Felding-Habermann, B. (2011). Contribution of platelets to tumour metastasis. Nature Reviews. Cancer, 11(2), 123–134.PubMedCrossRef
89.
Gay, L. J., & Felding-Habermann, B. (2011). Platelets alter tumor cell attributes to propel metastasis: programming in transit. Cancer Cell, 20(5), 553–554.PubMedCrossRef
90.
Kyriazi, V., & Theodoulou, E. (2013). Assessing the risk and prognosis of thrombotic complications in cancer patients. Archives of Pathology & Laboratory Medicine, 137(9), 1286–1295.CrossRef
91.
McEver, R. P. (1997). Selectin-carbohydrate interactions during inflammation and metastasis. Glycoconjugate Journal, 14(5), 585–591.PubMedCrossRef
92.
Dangel, O., Mergia, E., Karlisch, K., Groneberg, D., Koesling, D., & Friebe, A. (2010). Nitric oxide-sensitive guanylyl cyclase is the only nitric oxide receptor mediating platelet inhibition. Journal of Thrombosis and Haemostasis, 8(6), 1343–1352.PubMedCrossRef
93.
Koziak, K., Sevigny, J., Robson, S. C., Siegel, J. B., & Kaczmarek, E. (1999). Analysis of CD39/ATP diphosphohydrolase (ATPDase) expression in endothelial cells, platelets and leukocytes. Thrombosis and Haemostasis, 82(5), 1538–1544.PubMed
94.
Moncada, S., Gryglewski, R., Bunting, S., & Vane, J. R. (1976). An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature, 263(5579), 663–665.PubMedCrossRef
95.
Sabetkar, M., Naseem, K. M., Tullett, J. M., Friebe, A., Koesling, D., & Bruckdorfer, K. R. (2001). Synergism between nitric oxide and hydrogen peroxide in the inhibition of platelet function: the roles of soluble guanylyl cyclase and vasodilator-stimulated phosphoprotein. Nitric Oxide, 5(3), 233–242.PubMedCrossRef
96.
Zimmermann, H. (1999). Nucleotides and cd39: principal modulatory players in hemostasis and thrombosis. Nature Medicine, 5(9), 987–988.PubMedCrossRef
97.
Aleman, M. M., Gardiner, C., Harrison, P., & Wolberg, A. S. (2011). Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. Journal of Thrombosis and Haemostasis, 9(11), 2251–2261.PubMedPubMedCentralCrossRef
98.
Feng, D., Nagy, J. A., Pyne, K., Dvorak, H. F., & Dvorak, A. M. (1998). Platelets exit venules by a transcellular pathway at sites of F-met peptide-induced acute inflammation in guinea pigs. International Archives of Allergy and Immunology, 116(3), 188–195.PubMedCrossRef
99.
Gawaz, M., & Vogel, S. (2013). Platelets in tissue repair: control of apoptosis and interactions with regenerative cells. Blood, 122(15), 2550–2554.PubMedCrossRef
100.
Lowenhaupt, R. W., Glueck, H. I., Miller, M. A., & Kline, D. L. (1977). Factors which influence blood platelet migration. The Journal of Laboratory and Clinical Medicine, 90(1), 37–45.PubMed
101.
Nathan, P. (1973). The migration of human platelets in vitro. Thrombosis et Diathesis Haemorrhagica, 30(1), 173–177.PubMed
102.
Schmidt, E. M., Munzer, P., Borst, O., Kraemer, B. F., Schmid, E., Urban, B., et al. (2011). Ion channels in the regulation of platelet migration. Biochemical and Biophysical Research Communications, 415(1), 54–60.PubMedCrossRef
103.
Banerjee, D., Mazumder, S., & Kumar Sinha, A. (2016). Involvement of nitric oxide on calcium mobilization and arachidonic acid pathway activation during platelet aggregation with different aggregating agonists. International Journal of Biomedical Sciences, 12(1), 25–35.
104.
Philipose, S., Konya, V., Lazarevic, M., Pasterk, L. M., Marsche, G., Frank, S., et al. (2012). Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation. PloS One, 7(8), e40222.PubMedPubMedCentralCrossRef
105.
Feletou, M., Huang, Y., & Vanhoutte, P. M. (2010). Vasoconstrictor prostanoids. Pflügers Archiv, 459(6), 941–950.PubMedCrossRef
106.
Kandhi, S., Zhang, B., Froogh, G., Qin, J., Alruwali, N., Le, Y., et al. (2017). EETs promote hypoxic pulmonary vasoconstriction via constrictor prostanoids. American Journal of Physiology. Lung Cellular and Molecular Physiology ajplung 00038 02017.
107.
Bhagwat, S. S., Hamann, P. R., Still, W. C., Bunting, S., & Fitzpatrick, F. A. (1985). Synthesis and structure of the platelet aggregation factor thromboxane A2. Nature, 315(6019), 511–513.CrossRef
108.
Hamberg, M., Svensson, J., & Samuelsson, B. (1975). Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proceedings of the National Academy of Sciences of the United States of America, 72(8), 2994–2998.PubMedPubMedCentralCrossRef
109.
Fukami, M. H., & Salganicoff, L. (1977). Human platelet storage organelles. A review. Thrombosis and Haemostasis, 38(4), 963–970.PubMed
110.
Koseoglu, S., & Flaumenhaft, R. (2013). Advances in platelet granule biology. Current Opinion in Hematology, 20(5), 464–471.PubMedCrossRef
111.
Wihlborg, A. K., Wang, L., Braun, O. O., Eyjolfsson, A., Gustafsson, R., Gudbjartsson, T., et al. (2004). ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(10), 1810–1815.PubMedCrossRef
112.
Goschnick, M. W., & Jackson, D. E. (2007). Tetraspanins-structural and signalling scaffolds that regulate platelet function. Mini Reviews in Medicinal Chemistry, 7(12), 1248–1254.PubMedCrossRef
113.
Haining, E. J., Yang, J., & Tomlinson, M. G. (2011). Tetraspanin microdomains: fine-tuning platelet function. Biochemical Society Transactions, 39(2), 518–523.PubMedCrossRef
114.
Protty, M. B., Watkins, N. A., Colombo, D., Thomas, S. G., Heath, V. L., Herbert, J. M., et al. (2009). Identification of Tspan9 as a novel platelet tetraspanin and the collagen receptor GPVI as a component of tetraspanin microdomains. Biochemical Journal, 417(1), 391–400.PubMedCrossRef
115.
Israels, S. J., McMillan, E. M., Robertson, C., Singhory, S., & McNicol, A. (1996). The lysosomal granule membrane protein, LAMP-2, is also present in platelet dense granule membranes. Thrombosis and Haemostasis, 75(4), 623–629.PubMed
116.
Xu, L., Harada, H., & Taniguchi, A. (2008). The effects of LAMP1 and LAMP3 on M180 amelogenin uptake, localization and amelogenin mRNA induction by amelogenin protein. Journal of Biochemistry, 144(4), 531–537.PubMedCrossRef
117.
Vanags, D. M., Rodgers, S. E., Duncan, E. M., Lloyd, J. V., & Bochner, F. (1992). Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline. British Journal of Pharmacology, 106(4), 917–923.PubMedPubMedCentralCrossRef
118.
Petito, E., Momi, S., & Gresele, P. (2017). The migration of platelets and their interaction with other migrating cells. In P. Gresele, N. Kleiman, J. Lopez, & C. Page (Eds.), Platelets in thrombotic and non-thrombotic disorders (Vol. 2, pp. 337–351). Switzerland: Springer International Publishing.CrossRef
119.
Sandri, G., Bonferoni, M. C., Rossi, S., Ferrari, F., Mori, M., Cervio, M., et al. (2015). Platelet lysate embedded scaffolds for skin regeneration. Expert Opinion on Drug Delivery, 12(4), 525–545.PubMedCrossRef
120.
121.
Mancuso, M. E., & Santagostino, E. (2017). Platelets: much more than bricks in a breached wall. British Journal of Haematology, 4, 1–10.
122.
Anitua, E., Troya, M., Zalduendo, M., & Orive, G. (2017). Personalized plasma-based medicine to treat age-related diseases. Materials Science & Engineering. C, Materials for Biological Applications, 74, 459–464.CrossRef
123.
Meschi, N., Castro, A. B., Vandamme, K., Quirynen, M., & Lambrechts, P. (2016). The impact of autologous platelet concentrates on endodontic healing: a systematic review. Platelets, 27(7), 613–633.PubMedCrossRef
124.
Mlynarek, R. A., Kuhn, A. W., & Bedi, A. (2016). Platelet-rich plasma (PRP) in orthopedic sports medicine. American Journal of Orthopedics (Belle Mead, N.J.), 45(5), 290–326.
125.
Goubran, H. A., Stakiw, J., Radosevic, M., & Burnouf, T. (2014). Platelets effects on tumor growth. Seminars in Oncology, 41(3), 359–369.PubMedCrossRef
126.
Unwith, S., Zhao, H., Hennah, L., & Ma, D. (2015). The potential role of HIF on tumour progression and dissemination. International Journal of Cancer, 136(11), 2491–2503.PubMedCrossRef
127.
Schmidt, E. M., Kraemer, B. F., Borst, O., Munzer, P., Schonberger, T., Schmidt, C., et al. (2012). SGK1 sensitivity of platelet migration. Cellular Physiology and Biochemistry, 30(1), 259–268.PubMedCrossRef
128.
Kraemer, B. F., Borst, O., Gehring, E. M., Schoenberger, T., Urban, B., Ninci, E., et al. (2010). PI3 kinase-dependent stimulation of platelet migration by stromal cell-derived factor 1 (SDF-1). Journal of Molecular Medicine (Berlin), 88(12), 1277–1288.CrossRef
129.
Brandt, E., Ludwig, A., Petersen, F., & Flad, H. D. (2000). Platelet-derived CXC chemokines: old players in new games. Immunological Reviews, 177, 204–216.PubMedCrossRef
130.
Stone, R. L., Nick, A. M., McNeish, I. A., Balkwill, F., Han, H. D., Bottsford-Miller, J., et al. (2012). Paraneoplastic thrombocytosis in ovarian cancer. The New England Journal of Medicine, 366(7), 610–618.PubMedPubMedCentralCrossRef
131.
Kraemer, B. F., Schmidt, C., Urban, B., Bigalke, B., Schwanitz, L., Koch, M., et al. (2011). High shear flow induces migration of adherent human platelets. Platelets, 22(6), 415–421.PubMedCrossRef
132.
Chatterjee, M., Huang, Z., Zhang, W., Jiang, L., Hultenby, K., Zhu, L., et al. (2011). Distinct platelet packaging, release, and surface expression of proangiogenic and antiangiogenic factors on different platelet stimuli. Blood, 117(14), 3907–3911.PubMedCrossRef
133.
Shenkman, B., Brill, A., Brill, G., Lider, O., Savion, N., & Varon, D. (2004). Differential response of platelets to chemokines: RANTES non-competitively inhibits stimulatory effect of SDF-1 alpha. Journal of Thrombosis and Haemostasis, 2(1), 154–160.PubMedCrossRef
134.
Gleissner, C. A., von Hundelshausen, P., & Ley, K. (2008). Platelet chemokines in vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(11), 1920–1927.PubMedPubMedCentralCrossRef
135.
Rossaint, J., & Zarbock, A. (2015). Platelets in leucocyte recruitment and function. Cardiovascular Research, 107(3):386–95.
136.
Garraud, O., Berthet, J., Hamzeh-Cognasse, H., & Cognasse, F. (2011). Pathogen sensing, subsequent signalling, and signalosome in human platelets. Thrombosis Research, 127(4), 283–286.PubMedCrossRef
137.
von Hundelshausen, P., & Weber, C. (2007). Platelets as immune cells: bridging inflammation and cardiovascular disease. Circulation Research, 100(1), 27–40.CrossRef
138.
Rath, D., Chatterjee, M., Borst, O., Muller, K., Langer, H., Mack, A. F., et al. (2015). Platelet surface expression of stromal cell-derived factor-1 receptors CXCR4 and CXCR7 is associated with clinical outcomes in patients with coronary artery disease. Journal of Thrombosis and Haemostasis, 13(5), 719–728.PubMedCrossRef
139.
Rafii, S., Cao, Z., Lis, R., Siempos, I. I., Chavez, D., Shido, K., et al. (2015). Platelet-derived SDF-1 primes the pulmonary capillary vascular niche to drive lung alveolar regeneration. Nature Cell Biology, 17(2), 123–136.PubMedPubMedCentralCrossRef
140.
Chatterjee, M., Seizer, P., Borst, O., Schonberger, T., Mack, A., Geisler, T., et al. (2014). SDF-1alpha induces differential trafficking of CXCR4-CXCR7 involving cyclophilin A, CXCR7 ubiquitination and promotes platelet survival. The FASEB Journal, 28(7), 2864–2878.PubMedCrossRef
141.
Rath, D., Chatterjee, M., Borst, O., Muller, K., Stellos, K., Mack, A. F., et al. (2014). Expression of stromal cell-derived factor-1 receptors CXCR4 and CXCR7 on circulating platelets of patients with acute coronary syndrome and association with left ventricular functional recovery. European Heart Journal, 35(6), 386–394.PubMedCrossRef
142.
Iannacone, M. (2016). Platelet-mediated modulation of adaptive immunity. Seminars in Immunology, 28(6), 555–560.PubMedCrossRef
143.
Danese, S., & Fiocchi, C. (2016). Endothelial cell-immune cell interaction in IBD. Digestive Diseases, 34(1–2), 43–50.PubMedCrossRef
144.
Chatterjee, M., & Geisler, T. (2016). Inflammatory contribution of platelets revisited: new players in the arena of inflammation. Seminars in Thrombosis and Hemostasis, 42(3), 205–214.PubMedCrossRef
145.
Carestia, A., Kaufman, T., & Schattner, M. (2016). Platelets: new bricks in the building of neutrophil extracellular traps. Frontiers in Immunology, 7, 271.PubMedPubMedCentralCrossRef
146.
Lam, F. W., Vijayan, K. V., & Rumbaut, R. E. (2015). Platelets and their interactions with other immune cells. Comprehensive Physiology, 5(3), 1265–1280.PubMedPubMedCentralCrossRef
147.
Kapur, R., Zufferey, A., Boilard, E., & Semple, J. W. (2015). Nouvelle cuisine: platelets served with inflammation. Journal of Immunology, 194(12), 5579–5587.CrossRef
148.
Cognasse, F., Nguyen, K. A., Damien, P., McNicol, A., Pozzetto, B., Hamzeh-Cognasse, H., et al. (2015). The inflammatory role of platelets via their TLRs and Siglec receptors. Frontiers in Immunology, 6, 83.PubMedPubMedCentralCrossRef
149.
Chatterjee, M., Rath, D., & Gawaz, M. (2015). Role of chemokine receptors CXCR4 and CXCR7 for platelet function. Biochemical Society Transactions, 43(4), 720–726.PubMedCrossRef
150.
Varki, A. (2011). Since there are PAMPs and DAMPs, there must be SAMPs? Glycan “self-associated molecular patterns” dampen innate immunity, but pathogens can mimic them. Glycobiology, 21(9), 1121–1124.PubMedPubMedCentralCrossRef
151.
Menter, D. G., Steinert, B. W., Sloane, B. F., Taylor, J. D., & Honn, K. V. (1987). A new in vitro model for investigation of tumor cell-platelet-endothelial cell interactions and concomitant eicosanoid biosynthesis. Cancer Research, 47(9), 2425–2432.PubMed
152.
Chopra, H., Timar, J., Rong, X., Grossi, I. M., Hatfield, J. S., Fligiel, S. E., et al. (1992). Is there a role for the tumor cell integrin alpha IIb beta 3 and cytoskeleton in tumor cell-platelet interaction? Clinical & Experimental Metastasis, 10(2), 125–137.CrossRef
153.
Bennett, J. S., Zigmond, S., Vilaire, G., Cunningham, M. E., & Bednar, B. (1999). The platelet cytoskeleton regulates the affinity of the integrin alpha(IIb)beta(3) for fibrinogen. The Journal of Biological Chemistry, 274(36), 25301–25307.PubMedCrossRef
154.
Breckenridge, M. T., Egelhoff, T. T., & Baskaran, H. (2010). A microfluidic imaging chamber for the direct observation of chemotactic transmigration. Biomedical Microdevices, 12(3), 543–553.PubMedPubMedCentralCrossRef
155.
Ellingsen, T., Storgaard, M., Moller, B. K., Buus, A., Andersen, P. L., Obel, N., et al. (2000). Migration of mononuclear cells in the modified Boyden chamber as evaluated by DNA quantification and flow cytometry. Scandinavian Journal of Immunology, 52(3), 257–263.PubMedCrossRef
156.
Friedl, P., Wolf, K., & Lammerding, J. (2011). Nuclear mechanics during cell migration. Current Opinion in Cell Biology, 23(1), 55–64.PubMedCrossRef
157.
Bdeir, K., Gollomp, K., Stasiak, M., Mei, J., Papiewska-Pajak, I., Zhao, G., et al. (2017). Platelet-specific chemokines contribute to the pathogenesis of acute lung injury. American Journal of Respiratory Cell and Molecular Biology, 56(2), 261–270.PubMed
158.
Bruce, I. J., & Kerry, R. (1987). The effect of chloramphenicol and cycloheximide on platelet aggregation and protein synthesis. Biochemical Pharmacology, 36(11), 1769–1773.PubMedCrossRef
159.
Borisova, T. A., & Markosian, R. A. (1977). Age and biosynthesis and breakdown of thrombocyte proteins. Biulleten' Eksperimental'noĭ Biologii i Meditsiny, 83(1), 20–21.PubMed
160.
Pagel, O., Walter, E., Jurk, K., & Zahedi, R. P. (2017). Taking the stock of granule cargo: platelet releasate proteomics. Platelets, 28(2), 119–128.PubMedCrossRef
161.
Melki, I., Tessandier, N., Zufferey, A., & Boilard, E. (2017). Platelet microvesicles in health and disease. Platelets, 28(3), 214–221.PubMedCrossRef
162.
Wang, Z. T., Wang, Z., & Hu, Y. W. (2016). Possible roles of platelet-derived microparticles in atherosclerosis. Atherosclerosis, 248, 10–16.PubMedCrossRef
163.
164.
Cointe, S., Lacroix, R., & Dignat-George, F. (2017). Platelet-derived microparticles. In P. Gresele, N. Kleiman, J. Lopez, & C. Page (Eds.), Platelets in thrombotic and non-thrombotic disorders (Vol. 2, pp. 379–392). Switzerland: Springer International Publishing.CrossRef
165.
Zilberman-Rudenko, J., Sylman, J. L., Lakshmanan, H. H. S., McCarty, O. J. T., & Maddala, J. (2017). Dynamics of blood flow and thrombus formation in a multi-bypass microfluidic ladder network. Cellular and Molecular Bioengineering, 10(1), 16–29.PubMedCrossRef
166.
Whyte, C. S., Mitchell, J. L., & Mutch, N. J. (2017). Platelet-mediated modulation of fibrinolysis. Seminars in Thrombosis and Hemostasis, 43(2), 115–128.PubMedCrossRef
167.
Biolik, G., Kokot, M., Sznapka, M., Swieszek, A., Ziaja, D., Pawlicki, K., et al. (2017). Platelet reactivity in thromboelastometry. Revision of the FIBTEM test: a basic study. Scandinavian Journal of Clinical and Laboratory Investigation, 77(3), 216–222.PubMedCrossRef
168.
Mammadova-Bach, E., Ollivier, V., Loyau, S., Schaff, M., Dumont, B., Favier, R., et al. (2015). Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. Blood, 126(5), 683–691.PubMedCrossRef
169.
Kral, J. B., Schrottmaier, W. C., Salzmann, M., & Assinger, A. (2016). Platelet interaction with innate immune cells. Transfusion Medicine and Hemotherapy, 43(2), 78–88.PubMedPubMedCentralCrossRef
170.
Clark, S. R., Ma, A. C., Tavener, S. A., McDonald, B., Goodarzi, Z., Kelly, M. M., et al. (2007). Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nature Medicine, 13(4), 463–469.PubMedCrossRef
171.
Joshi, S., & Whiteheart, S. W. (2017). The nuts and bolts of the platelet release reaction. Platelets, 28(2), 129–137.PubMedCrossRef
172.
Suades, R., Padro, T., & Badimon, L. (2015). The role of blood-borne microparticles in inflammation and hemostasis. Seminars in Thrombosis and Hemostasis, 41(6), 590–606.PubMedCrossRef
173.
Gill, P., Jindal, N. L., Jagdis, A., & Vadas, P. (2015). Platelets in the immune response: revisiting platelet-activating factor in anaphylaxis. The Journal of Allergy and Clinical Immunology, 135(6), 1424–1432.PubMedCrossRef
174.
Momi, S., & Wiwanitkit, V. (2017). Phylogeny of blood platelets. In P. Gresele, N. Kleiman, J. Lopez, & C. Page (Eds.), Platelets in thrombotic and non-thrombotic disorders (Vol. 2, pp. 11–19). Switzerland: Springer International Publishing.CrossRef
175.
Roch, G. J., & Sherwood, N. M. (2014). Glycoprotein hormones and their receptors emerged at the origin of metazoans. Genome Biology and Evolution, 6(6), 1466–1479.PubMedPubMedCentralCrossRef
176.
He, W., Tang, Y., Qi, B., Lu, C., Qin, C., Wei, Y., et al. (2014). Phylogenetic analysis and positive-selection site detecting of vascular endothelial growth factor family in vertebrates. Gene, 535(2), 345–352.PubMedCrossRef
177.
Mercer, P. F., & Chambers, R. C. (2013). Coagulation and coagulation signalling in fibrosis. Biochimica et Biophysica Acta, 1832(7), 1018–1027.PubMedCrossRef
178.
Yamaguchi, Y., & Yoshikawa, K. (2001). Cutaneous wound healing: an update. The Journal of Dermatology, 28(10), 521–534.PubMedCrossRef
179.
Gerarduzzi, C., & Di Battista, J. A. (2017). Myofibroblast repair mechanisms post-inflammatory response: a fibrotic perspective. Inflammation Research, 66(6), 451–465.PubMedCrossRef
180.
Greaves, N. S., Ashcroft, K. J., Baguneid, M., & Bayat, A. (2013). Current understanding of molecular and cellular mechanisms in fibroplasia and angiogenesis during acute wound healing. Journal of Dermatological Science, 72(3), 206–217.PubMedCrossRef
181.
Carthy, J. M. (2017). TGFbeta signaling and the control of myofibroblast differentiation: implications for chronic inflammatory disorders. Journal of Cellular Physiology. doi:10.​1002/​jcp.​25879.
182.
Ghosh, D., McGrail, D. J., & Dawson, M. R. (2017). TGF-beta1 pretreatment improves the function of mesenchymal stem cells in the wound bed. Frontiers in Cell and Development Biology, 5, 28.CrossRef
183.
Valcourt, U., Carthy, J., Okita, Y., Alcaraz, L., Kato, M., Thuault, S., et al. (2016). Analysis of epithelial-mesenchymal transition induced by transforming growth factor beta. Methods in Molecular Biology, 1344, 147–181.PubMedCrossRef
184.
Das, U. N. (2016). Inflammatory bowel disease as a disorder of an imbalance between pro- and anti-inflammatory molecules and deficiency of resolution bioactive lipids. Lipids in Health and Disease, 15, 11.PubMedPubMedCentralCrossRef
185.
Gensel, J. C., & Zhang, B. (2015). Macrophage activation and its role in repair and pathology after spinal cord injury. Brain Research, 1619, 1–11.PubMedCrossRef
186.
Shinde, A. V., & Frangogiannis, N. G. (2014). Fibroblasts in myocardial infarction: a role in inflammation and repair. Journal of Molecular and Cellular Cardiology, 70, 74–82.PubMedCrossRef
187.
Arwert, E. N., Hoste, E., & Watt, F. M. (2012). Epithelial stem cells, wound healing and cancer. Nature Reviews. Cancer, 12(3), 170–180.PubMedCrossRef
188.
Dovizio, M., Sacco, A., & Patrignani, P. (2017). Curbing tumorigenesis and malignant progression through the pharmacological control of the wound healing process. Vascular Pharmacology, 89, 1–11.PubMedCrossRef
189.
190.
Lichtenberger, L., Fang, D., Bick, R., Poindexter, B., Phan, T., Bergeron, A., et al. (2017). Unlocking aspirin's chemopreventive activity: role of irreversibly inhibiting platelet cyclooxygenase-1. Cancer Prevention Reseach, 10, 142–152.CrossRef
191.
Menter, D. G., Hatfield, J. S., Harkins, C., Sloane, B. F., Taylor, J. D., Crissman, J. D., et al. (1987). Tumor cell-platelet interactions in vitro and their relationship to in vivo arrest of hematogenously circulating tumor cells. Clinical & Experimental Metastasis, 5(1), 65–78.CrossRef
192.
Menter, D. G., Harkins, C., Onoda, J., Riorden, W., Sloane, B. F., Taylor, J. D., et al. (1987). Inhibition of tumor cell induced platelet aggregation by prostacyclin and carbacyclin: an ultrastructural study. Invasion & Metastasis, 7(2), 109–128.
193.
Umar, A., Steele, V. E., Menter, D. G., & Hawk, E. T. (2016). Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. Seminars in Oncology, 43(1), 65–77.PubMedCrossRef
194.
Drew, D. A., Cao, Y., & Chan, A. T. (2016). Aspirin and colorectal cancer: the promise of precision chemoprevention. Nature Reviews. Cancer, 16(3), 173–186.PubMedCrossRef
195.
Holmes, C. E., Jasielec, J., Levis, J. E., Skelly, J., & Muss, H. B. (2013). Initiation of aspirin therapy modulates angiogenic protein levels in women with breast cancer receiving tamoxifen therapy. Clinical and Translational Science, 6(5), 386–390.PubMedPubMedCentralCrossRef
196.
Bardia, A., Ebbert, J. O., Vierkant, R. A., Limburg, P. J., Anderson, K., Wang, A. H., et al. (2007). Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. Journal of the National Cancer Institute, 99(11), 881–889.PubMedCrossRef
197.
Bosetti, C., Rosato, V., Gallus, S., Cuzick, J., & La Vecchia, C. (2012). Aspirin and cancer risk: a quantitative review to 2011. Annals of Oncology, 23(6), 1403–1415.PubMedCrossRef
198.
Chan, A. T., Manson, J. E., Feskanich, D., Stampfer, M. J., Colditz, G. A., & Fuchs, C. S. (2007). Long-term aspirin use and mortality in women. Archives of Internal Medicine, 167(6), 562–572.PubMedCrossRef
199.
Ratnasinghe, L. D., Graubard, B. I., Kahle, L., Tangrea, J. A., Taylor, P. R., & Hawk, E. (2004). Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Research, 24(5B), 3177–3184.PubMed
200.
Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., et al. (2003). A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. The New England Journal of Medicine, 348(10), 883–890.PubMedCrossRef
201.
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., et al. (2003). A randomized trial of aspirin to prevent colorectal adenomas. The New England Journal of Medicine, 348(10), 891–899.PubMedCrossRef
202.
Burn, J., Gerdes, A. M., Macrae, F., Mecklin, J. P., Moeslein, G., Olschwang, S., et al. (2011). Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet, 378(9809), 2081–2087.PubMedPubMedCentralCrossRef
203.
Drew, D. A., Chin, S. M., Gilpin, K. K., Parziale, M., Pond, E., Schuck, M. M., et al. (2017). ASPirin intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial. Trials, 18(1), 50.PubMedPubMedCentralCrossRef
204.
Honn, K. V., Cicone, B., & Skoff, A. (1981). Prostacyclin: a potent antimetastatic agent. Science, 212(4500), 1270–1272.PubMedCrossRef
205.
Honn, K. V., Menter, D., Cavanaugh, P. G., Neagos, G., Moilanen, D., Taylor, J. D., et al. (1983). A review of prostaglandins and the treatment of tumor metastasis. Acta Clinica Belgica, 38(1), 53–67.PubMedCrossRef
206.
Gasic, G. J., Gasic, T. B., & Stewart, C. C. (1968). Antimetastatic effects associated with platelet reduction. Proceedings of the National Academy of Sciences of the United States of America, 61(1), 46–52.PubMedPubMedCentralCrossRef
207.
Woods, J. R. (1964). Experimental studies of the intravascular dissemination of Ascitic V2 carcinoma cells in the rabbit, with special reference to fibrinogen and fibrinolytic agents. Bulletin der Schweizerischen Akademie der Medizinischen Wissenschaften, 20, 92–121.PubMed
208.
Horejsova, M., Pavlickova, V., Koukolik, F., & Strritesky, J. (1995). Morphologic verification of neoplastic portal vein obstruction. Casopís Lékar̆ů C̆eských, 134(20), 655–657.PubMed
209.
Benazzi, C., Al-Dissi, A., Chau, C. H., Figg, W. D., Sarli, G., de Oliveira, J. T., et al. (2014). Angiogenesis in spontaneous tumors and implications for comparative tumor biology. ScientificWorldJournal, 2014, 919570.PubMedPubMedCentralCrossRef
210.
Fein, M. R., & Egeblad, M. (2013). Caught in the act: revealing the metastatic process by live imaging. Disease Models & Mechanisms, 6(3), 580–593.CrossRef
211.
Starke, J., Wehrle-Haller, B., & Friedl, P. (2014). Plasticity of the actin cytoskeleton in response to extracellular matrix nanostructure and dimensionality. Biochemical Society Transactions, 42(5), 1356–1366.PubMedCrossRef
212.
Gritsenko, P. G., Ilina, O., & Friedl, P. (2012). Interstitial guidance of cancer invasion. The Journal of Pathology, 226(2), 185–199.PubMedCrossRef
213.
Friedl, P., Sahai, E., Weiss, S., & Yamada, K. M. (2012). New dimensions in cell migration. Nature Reviews. Molecular Cell Biology, 13(11), 743–747.PubMedCrossRef
214.
Friedl, P., Wolf, K., & Zegers, M. M. (2014). Rho-directed forces in collective migration. Nature Cell Biology, 16(3), 208–210.PubMedCrossRef
215.
Haeger, A., Krause, M., Wolf, K., & Friedl, P. (2014). Cell jamming: collective invasion of mesenchymal tumor cells imposed by tissue confinement. Biochimica et Biophysica Acta, 1840(8), 2386–2395.PubMedCrossRef
216.
Deng, G., Krishnakumar, S., Powell, A. A., Zhang, H., Mindrinos, M. N., Telli, M. L., et al. (2014). Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. BMC Cancer, 14, 456.PubMedPubMedCentralCrossRef
217.
Powell, A. A., Talasaz, A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., et al. (2012). Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PloS One, 7(5), e33788.PubMedPubMedCentralCrossRef
218.
Tang, J., Gao, X., Zhi, M., Zhou, H. M., Zhang, M., Chen, H. W., et al. (2015). Plateletcrit: a sensitive biomarker for evaluating disease activity in Crohn's disease with low hs-CRP. Journal of Digestive Diseases, 16(3), 118–124.PubMedCrossRef
219.
Pasula, S., Cai, X., Dong, Y., Messa, M., McManus, J., Chang, B., et al. (2012). Endothelial epsin deficiency decreases tumor growth by enhancing VEGF signaling. The Journal of Clinical Investigation, 122(12), 4424–4438.PubMedPubMedCentralCrossRef
220.
Hellberg, C., Ostman, A., & Heldin, C. H. (2010). PDGF and vessel maturation. Recent Results in Cancer Research, 180, 103–114.PubMedCrossRef
221.
Carmeliet, P. (2005). VEGF as a key mediator of angiogenesis in cancer. Oncology, 69(Suppl 3), 4–10.PubMedCrossRef
222.
Keskin, D., Kim, J., Cooke, V. G., Wu, C. C., Sugimoto, H., Gu, C., et al. (2015). Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2. Cell Reports, 10(7), 1066–1081.PubMedPubMedCentralCrossRef
223.
Nagy, J. A., Dvorak, A. M., & Dvorak, H. F. (2012). Vascular hyperpermeability, angiogenesis, and stroma generation. Cold Spring Harbor Perspectives in Medicine, 2(2), a006544.PubMedPubMedCentralCrossRef
224.
225.
Kisucka, J., Butterfield, C. E., Duda, D. G., Eichenberger, S. C., Saffaripour, S., Ware, J., et al. (2006). Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proceedings of the National Academy of Sciences of the United States of America, 103(4), 855–860.PubMedPubMedCentralCrossRef
226.
Schumacher, D., Strilic, B., Sivaraj, K. K., Wettschureck, N., & Offermanns, S. (2013). Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell, 24(1), 130–137.PubMedCrossRef
227.
O'Byrne, K. J., & Steward, W. P. (2001). Tumour angiogenesis: a novel therapeutic target in patients with malignant disease. Expert Opinion on Emerging Drugs, 6(1), 155–174.PubMed
228.
Satelli, A., Mitra, A., Brownlee, Z., Xia, X., Bellister, S., Overman, M. J., et al. (2015). Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clinical Cancer Research, 21(4), 899–906.PubMedCrossRef
229.
Labelle, M., & Hynes, R. O. (2012). The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discovery, 2(12), 1091–1099.PubMedPubMedCentralCrossRef
230.
Labelle, M., Begum, S., & Hynes, R. O. (2011). Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell, 20(5), 576–590.PubMedPubMedCentralCrossRef
231.
van Es, N., Sturk, A., Middeldorp, S., & Nieuwland, R. (2014). Effects of cancer on platelets. Seminars in Oncology, 41(3), 311–318.PubMedCrossRef
232.
Nistico, P., Bissell, M. J., & Radisky, D. C. (2012). Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harbor Perspectives in Biology, 4(2), 1–10.
233.
Gresele, P., Falcinelli, E., Sebastiano, M., & Momi, S. (2017). Matrix metalloproteinases and platelet function. Progress in Molecular Biology and Translational Science, 147, 133–165.PubMedCrossRef
234.
Fidler, I. J. (1978). Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Research, 38(9), 2651–2660.PubMed
235.
Billroth, T. (1878). Lectures on surgical pathology and therapeutics, a handbook for students and practitioners (Vol. II). London: The New Sydenham Society.
236.
Johnson, J. H., & Woods, J. R. (1963). An in vitro study of fibrinolytic agents on V2 carcinoma cells and intravascular thrombi in rabbits. Bulletin of the Johns Hopkins Hospital, 113, 335–346.PubMed
237.
Baserga, R., & Saffiotti, U. (1955). Experimental studies on histogenesis of blood-borne metastases. A.M.A. Archives of Pathology, 59(1), 26–34.PubMed
238.
Jones, D. S., Wallace, A. C., & Fraser, E. E. (1971). Sequence of events in experimental metastases of Walker 256 tumor: light, immunofluorescent, and electron microscopic observations. Journal of the National Cancer Institute, 46(3), 493–504.PubMed
239.
Chew, E. C., & Wallace, A. C. (1976). Demonstration of fibrin in early stages of experimental metastases. Cancer Research, 36(6), 1904–1909.PubMed
240.
Warren, B. A., & Vales, O. (1972). The adhesion of thromboplastic tumour emboli to vessel walls in vivo. British Journal of Experimental Pathology, 53(3), 301–313.PubMedPubMedCentral
241.
Warren, B. A., & Vales, O. (1972). The release of vesicles from platelets following adhesion to vessel walls in vitro. British Journal of Experimental Pathology, 53(2), 206–215.PubMedPubMedCentral
242.
Warren, B. A. (1976). Some aspects of blood borne tumour emboli associated with thrombosis. Zeitschrift für Krebsforschung und Klinische Onkologie. Cancer Research and Clinical Oncology, 87(1), 1–15.PubMed
243.
Kinjo, M. (1978). Lodgement and extravasation of tumour cells in blood-borne metastasis: an electron microscope study. British Journal of Cancer, 38(2), 293–301.PubMedPubMedCentralCrossRef
244.
Gastpar, H. (1978). Inhibition of cancer cell stickiness, a model for the testing of in vivo thrombocyte aggregation inhibitors. IV. Effect of sulfinpyrazone. Fortschritte der Medizin, 96(36), 1823–1827.PubMed
245.
Paul, C. D., Mistriotis, P., & Konstantopoulos, K. (2017). Cancer cell motility: lessons from migration in confined spaces. Nature Reviews. Cancer, 17(2), 131–140.PubMedCrossRef
246.
Tonisen, F., Perrin, L., Bayarmagnai, B., van den Dries, K., Cambi, A., & Gligorijevic, B. (2017). EP4 receptor promotes invadopodia and invasion in human breast cancer. European Journal of Cell Biology, 96(2), 218–226.PubMedCrossRef
247.
Lonsdorf, A. S., Kramer, B. F., Fahrleitner, M., Schonberger, T., Gnerlich, S., Ring, S., et al. (2012). Engagement of alphaIIbbeta3 (GPIIb/IIIa) with alphanubeta3 integrin mediates interaction of melanoma cells with platelets: a connection to hematogenous metastasis. The Journal of Biological Chemistry, 287(3), 2168–2178.PubMedCrossRef
248.
Lichtenberger, L. M., Fang, D., Bick, R. J., Poindexter, B. J., Phan, T., Bergeron, A. L., et al. (2017). Unlocking aspirin’s chemopreventive activity: role of irreversibly inhibiting platelet cyclooxygenase-1. Cancer Prevention Research (Philadelphia, Pa.), 10(2), 142–152.CrossRef
249.
Hu, Q., Wang, M., Cho, M. S., Wang, C., Nick, A. M., Thiagarajan, P., et al. (2016). Lipid profile of platelets and platelet-derived microparticles in ovarian cancer. BBA Clin, 6, 76–81.PubMedPubMedCentralCrossRef
250.
Haemmerle, M., Bottsford-Miller, J., Pradeep, S., Taylor, M. L., Choi, H. J., Hansen, J. M., et al. (2016). FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. The Journal of Clinical Investigation, 126(5), 1885–1896.PubMedPubMedCentralCrossRef
251.
Qi, C., Li, B., Guo, S., Wei, B., Shao, C., Li, J., et al. (2015). P-selectin-mediated adhesion between platelets and tumor cells promotes intestinal tumorigenesis in Apc(min/+) mice. International Journal of Biological Sciences, 11(6), 679–687.PubMedPubMedCentralCrossRef
252.
Crissman, J. D., Hatfield, J., Schaldenbrand, M., Sloane, B. F., & Honn, K. V. (1985). Arrest and extravasation of B16 amelanotic melanoma in murine lungs. A light and electron microscopic study. Laboratory Investigation, 53(4), 470–478.PubMed
253.
Oleksowicz, L., Mrowiec, Z., Schwartz, E., Khorshidi, M., Dutcher, J. P., & Puszkin, E. (1995). Characterization of tumor-induced platelet aggregation: the role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells. Thrombosis Research, 79(3), 261–274.PubMedCrossRef
254.
Bouvenot, G., Escande, M., Xeridat, B., Simonin, G., Boucoiran, J., & Delboy, C. (1977). Thrombocytosis and cancer. Apropos of a chronological series of 100 patients. La Semaine des Hôpitaux, 53(36), 1921–1925.PubMed
255.
Honn, K. V., Tang, D. G., & Crissman, J. D. (1992). Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Reviews, 11(3–4), 325–351.PubMedCrossRef
256.
Levin, J., & Conley, C. L. (1964). Thrombocytosis associated with malignant disease. Archives of Internal Medicine, 114, 497–500.PubMedCrossRef
257.
Rank, A., Liebhardt, S., Zwirner, J., Burges, A., Nieuwland, R., & Toth, B. (2012). Circulating microparticles in patients with benign and malignant ovarian tumors. Anticancer Research, 32(5), 2009–2014.PubMed
258.
Nieuwland, R., Berckmans, R. J., Rotteveel-Eijkman, R. C., Maquelin, K. N., Roozendaal, K. J., Jansen, P. G., et al. (1997). Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation, 96(10), 3534–3541.PubMedCrossRef
259.
van Doormaal, F., Kleinjan, A., Berckmans, R. J., Mackman, N., Manly, D., Kamphuisen, P. W., et al. (2012). Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study. Thrombosis and Haemostasis, 108(1), 160–165.PubMedCrossRef
260.
Cokic, V. P., Mitrovic-Ajtic, O., Beleslin-Cokic, B. B., Markovic, D., Buac, M., Diklic, M., et al. (2015). Proinflammatory cytokine IL-6 and JAK-STAT signaling pathway in myeloproliferative neoplasms. Mediators of Inflammation, 2015, 453020.PubMedPubMedCentralCrossRef
261.
Matsuo, K., Hasegawa, K., Yoshino, K., Murakami, R., Hisamatsu, T., Stone, R. L., et al. (2015). Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. European Journal of Cancer, 51(14), 1978–1988.PubMedCrossRef
Metadata
Title
Platelet “first responders” in wound response, cancer, and metastasis
Authors
David G. Menter
Scott Kopetz
Ernest Hawk
Anil K. Sood
Jonathan M. Loree
Paolo Gresele
Kenneth V. Honn
Publication date
01-06-2017
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 2/2017
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-017-9682-0

Other articles of this Issue 2/2017

Cancer and Metastasis Reviews 2/2017 Go to the issue

OriginalPaper

Platelet-activating factor podoplanin: from discovery to drug development

NON-THEMATIC REVIEW

Cleavage and phosphorylation: important post-translational modifications of galectin-3

ReviewPaper

Normal platelet function

NON-THEMATIC REVIEW

Radiation-induced inflammatory cascade and its reverberating crosstalks as potential cause of post-radiotherapy second malignancies

Announcement

Biography—David Menter

OriginalPaper

Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits